Connect to Cure®
With its clinical-stage platform technology, Synaffix has established itself as the preferred technology provider enabling best-in-class targeted cancer therapeutics.
Connect to Innovate
Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.
Connect to Partner
Under a focused technology out-licensing business model, Synaffix has delivered multiple best-in-class therapeutic candidates for our partners’ pipelines.
Next-Generation ADCs Being Developed under License Agreements
Partner
Program
(Target)
Preclinical
Phase 1
Pivotal (Phase 2/3)
Partner / Licensee
IBI343
(Claudin 18.2)
IBI3001
(B7-H3xEGFR)
Partner / Licensee
MRG004A
(TF)
MRG007
(CDH17)
Partner / Licensee
MGC026
(B7-H3)
MGC028
(ADAM9)
2x Undisclosed
Partner / Licensee
XMT-1660
(B7-H4)
Partner / Licensee
in collaboration with Mersana Therapeutics, Inc.
Undisclosed
Partner / Licensee
KIVU-107
KIVU-305
KIVU-202
Partner / Licensee
2x Undisclosed
Partner / Licensee
2x Undisclosed
Partner / Licensee
CKD-703
(c-MET)
Partner / Licensee
EO-1022
(HER3)
Partner / Licensee
SOT109
(CDH17)
SOT112
(bispecific ADC)
SOT113
(bispecific ADC)
Partner / Licensee
HMBD-501
Partner / Licensee
2x Undisclosed
Partner / Licensee
Undisclosed
Partner / Licensee
Undisclosed
Partner / Licensee
Undisclosed
Partner / Licensee
Dual Payload
ADC
Next-Generation ADCs Being Developed that Contain Synaffix Technology
Organization
Program
(Target)
Preclinical
Phase 1
Pivotal (Phase 2/3)
Organization
National Cancer Institute*
*Sponsor of clinical trial of ADC containing Synaffix technology; this clinical trial is not subject to any license agreement between NCI and Synaffix
